PW Medtech Group Limited Issues Profit Warning: Key Details for Investors

Summary of Announcement

PW Medtech Group Limited (Stock Code: 1358) has issued a profit warning regarding its financial performance for the year ended December 31, 2025. This announcement was made in accordance with Rule 13.09 of the Listing Rules and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance, reflecting the company’s commitment to transparency and regulatory compliance.

Key Financial Highlights

• Net Profit Decline: The company expects a net profit in the range of RMB120 million to RMB147 million for FY2025, which represents a significant decrease of 38% to 24% compared to the net profit of approximately RMB192.5 million in FY2024.
• Profit Attributable to Owners: The profit attributable to the owners of the company is estimated at RMB83 million to RMB102 million for FY2025. This is a decrease of 45% to 32% compared to RMB150.8 million in FY2024.

Important Shareholder Information

• Primary Reason for Decline: The decrease in profits is primarily due to declining sales in the infusion set business segment. This is attributed to the near-complete implementation of centralized procurement policies, which has negatively impacted sales volumes.
• Status of Results: The reported figures are based on a preliminary review of unaudited consolidated management accounts. These numbers have not been audited or reviewed by the company’s auditors.
• Timeline for Audited Results: PW Medtech expects to publish its audited consolidated financial results for FY2025 on or before March 31, 2026.
• Board Composition: The Board currently consists of one executive director (Ms. Yue’e Zhang), two non-executive directors (Mr. Jiang Liwei and Mr. Lin Junshan), and three independent non-executive directors (Mr. Wang Xiaogang, Mr. Chen Geng, and Ms. Wang Fengli).

Potential Impact on Share Price

This profit warning is material and price-sensitive information for shareholders and potential investors. The significant drop in both net profit and profit attributable to owners, driven by structural changes in procurement policy impacting a core business segment, may adversely affect investor sentiment and the company’s share price.

Shareholders and potential investors are strongly advised to exercise caution when dealing in the shares of PW Medtech Group Limited.

Management Statement

The announcement was signed by Ms. Yue’e Zhang, Chairman & Chief Executive Officer, on March 9, 2026. The company reiterates its commitment to keeping investors informed and will provide further updates once the audited results are available.

Disclaimer

This article is based on preliminary unaudited figures and information provided by PW Medtech Group Limited. Investors should be aware that these figures are subject to change pending the completion of the audit process. The content herein should not be construed as investment advice, and readers are urged to consult with their financial advisors before making any investment decisions related to PW Medtech Group Limited.

View PW MEDTECH Historical chart here